16th Jul 2021 11:24
ImmuPharma PLC - pharmaceutical company based in London - Appoints Tim Franklin to the board of directors. Says Franklin has worked with the company for over three years and was appointed as chief operating officer in November 2020. Notes that Franklin currently holds 1.5 million options over ordinary shares in the company.
Says Franklin will lead collaboration with Avion Pharmaceuticals LLC, based in the US state of Georgia, to progress lupuzor through a phase-three trial and towards regulator approval. The two firms partnered in 2020 to develop lupazor, used to treat systemic lupus erythematosus, a potentially life-threatening autoimmune disease.
Franklin formerly worked in clinical research and sales for pharmaceutical companies Warner Lambert and SmithKline Beecham, which now is GlaxoSmithKline PLC. Previously, he was a pharmaceuticals analyst for German investment bank Dresdner Kleinwort.
Chair Tim McCarthy says: "[Franklin's] extensive pharmaceutical and capital markets experience will contribute enormously to the team as we look to move into the next phase of our journey for the company."
Current stock price: 8.85 pence, up 7.4% on Friday morning
Year-to-date change: down 34%
By Scarlett Butler; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ImmupharmaGlaxosmithkline